Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-07-28), Spero Therapeutics's 6-Month Price Index is 0.50.
Spero Therapeutics (NAS:SPRO) 6-Month Price Index Explanation
Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.
The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.
Spero Therapeutics 6-Month Price Index Related Terms
SPRO vs ACRV, BSEM, RNTX: 6-Month Price Index Comparison
For the Biotechnology subindustry, Spero Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics (NAS:SPRO) 6-Month Price Index Calculation
6-Month Price Index is calculated as following:
6-Month Price Index
=
Current Share Price
/
Share Price 6-Months Ago
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (SPRO) has a 6-Month Price Index of 0.50 as of Jul. 28, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Spero Therapeutics and its competitors.
Is Spero Therapeutics' 6-Month Price Index too high?
Spero Therapeutics' current 6-Month Price Index is 0.50. Overall, Spero Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' 6-Month Price Index compare to ACRV and BSEM?
Spero Therapeutics' 6-Month Price Index of 0.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current 6-Month Price Index is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $1.20 — trading 13.8% above its estimated fair value. The current 6-Month Price Index is 0.50. Spero Therapeutics' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current 6-Month Price Index is 0.50 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $1.20 is trading 13.8% above its estimated GF Value™ of $1.05.
GuruFocus considers Spero Therapeutics to be Modestly Overvalued.
Key valuation signals for SPRO:
6-Month Price Index: 0.50
GF Value™: $1.05 vs. price of $1.20 (13.8% above fair value)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
66GF Score
Get the complete analysis for SPRO
6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
